Centhaquin - Pharmazz

Drug Profile

Centhaquin - Pharmazz

Alternative Names: PMZ 2010

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Midwestern University; Pharmazz
  • Developer Pharmazz
  • Class Antihypertensives; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhagic shock
  • Phase I Postoperative pain

Most Recent Events

  • 03 Feb 2017 Phase-II clinical trials in Haemorrhagic shock in India (IV)
  • 31 Jan 2017 Pharmazz receives notice of issuance for Centhaquin for Resuscitation (hypotensive) in Japan
  • 12 Nov 2016 Pharmacokinetics data from a phase I trial in Haemorrhagic shock (In volunteers) presented at the 89th Annual Scientific Sessions of the American Heart Association (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top